Daratumumab plus bortezomib and dexamethasone (Dara-VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light-chain amyloidosis: Long-term follow-up results from a prospective phase 2 study.

Br J Haematol · 2026 · PMC13267439 · PMID 41850888

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

Notably, in a 6‐month landmark analysis of OS, the stage IIIB patients showed a trend towards inferior survival compared to stage IIIA patients ( p = 0.062) within the first 6 months.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.